Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 4/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12486421 | 0.89 | PDE4A (0.36) | PDE4B | |
| SCHEMBL2887418 | 0.85 | PDE4A (0.44) | PDE4B | |
| SCHEMBL8492806 | 0.84 | PDE4A (0.43) | PDE4B | |
| SCHEMBL12486463 | 0.82 | PDE4A (0.40) | PDE4B | |
| SCHEMBL315053 | 0.79 | PDE4A (0.48) | PDE4B | |
| SCHEMBL2885764 | 0.79 | PDE4A (0.44) | PDE4B | |
| SCHEMBL1780546 | 0.78 | HRH1 (0.62) | HTR1ASLC6A2SLC6A3HRH1PDE4B | |
| SCHEMBL6637719 | 0.78 | SLC6A2 (0.42) | SLC6A2SLC6A3HTR2CSLC6A4 | |
| Hydrochloric Acid SCHEMBL4100905 | 0.77 | HRH1 (0.60) | HTR1ASLC6A2SLC6A3HRH1PDE4B | |
| SCHEMBL5374046 | 0.75 | SLC6A2 (0.54) | HTR1ASLC6A2SLC6A3HRH1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267496-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-10-10 | — | — | US | claimed |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | claimed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | claimed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-9796718-B2 | 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine | GILEAD CONNECTICUT, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3123864-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2716157-B1 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160031894-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9212191-B2 | 6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor | GILEAD CONNECTICUT, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9120811-B2 | 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma | GILEAD CONNECTICUT, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237521-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8455493-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8450321-B2 | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor | GILEAD CONNECTICUT, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | disclosed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031894-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR1A 3998/4885SLC6A2 4770/4885SLC6A3 4751/4885 |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR1A 3998/4885SLC6A2 4770/4885SLC6A3 4751/4885 |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR1A 3998/4885SLC6A2 4770/4885SLC6A3 4751/4885 |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR1A 3998/4885SLC6A2 4770/4885SLC6A3 4751/4885 |
| US-20130267496-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR1A 3998/4885SLC6A2 4770/4885SLC6A3 4751/4885 |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HTR1A 3998/4885SLC6A2 4770/4885SLC6A3 4751/4885 |
| US-20130237521-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, ZAP70, BTK | HTR1A 4135/4885SLC6A2 4821/4885SLC6A3 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.